Scope, Claims, and U.S. Patent Landscape for Drug Patent No. 10,098,997 (Filter Apparatus for Removing Small-Molecule Chemotherapy Agents from Blood)
What does US Patent 10,098,997 claim, and what is the protected invention’s core scope?
Answer: U.S. Patent 10,098,997 claims a hemocompatible polymer-coated carbon-core filter apparatus that removes small-molecule chemotherapy agents from blood. The legal scope is anchored to (i) carbon cores with specific pore-volume and porosity ranges, (ii) specific surface-area metrics, and (iii) polymer coating chemistry, with dependent claims that lock performance for named drugs (melphalan HCl, doxorubicin, topotecan) and specific cartridges and flow rates.
Claim-1 anchor elements (independent claim scope)
Claim 1 requires all of the following in combination:
- Filter apparatus with a housing having an inlet and outlet
- Extraction media in the housing comprising hemocompatible polymer coated carbon cores
- Carbon cores have:
- Pore volume: about 1.68 cc/g to 2.17 cc/g
- Claim 1’s performance is not stated at the independent level; performance appears in later dependent claims (claims 10–14).
What makes the claim “tight” vs “broad”
This estate is materially constricted by structural and quantitative carbon characterization. Even if a competitor uses the same general concept (blood detoxification using carbon adsorbents), literal infringement is likely limited unless the competitor’s carbon cores fall within the claimed property windows.
What are the detailed claim limitations (quantified carbon properties) and how do they define infringement risk?
Answer: Claims 2–8 define multiple carbon-core metrics with narrow numeric ranges. A design-around that moves carbon properties outside even one claimed range can reduce literal infringement risk.
Carbon core geometry and density
- Claim 2 (particle diameter): about 0.45 mm to 1.15 mm
- Claim 3 (apparent density): about 0.19 cc/g to 0.2 cc/g
Microporous and mesoporous structure
- Claim 4 (micropore D50,micro): 9.3 Å to 10.5 Å
- Claim 5 (mesopore D50,meso): 30 Å to 156 Å
- Claim 6 (percent microporous pores, as % of pore volume): 18% to 28%
Surface-area metrics
- Claim 7 (MBET): 1825 m²/g to 2058 m²/g
- Claim 8 (DFT): 1483 m²/g to 1778 m²/g
Practical infringement reading
A party seeking to avoid the claim must manage multiple axes:
- carbon synthesis route,
- pore-size distribution (micro and meso),
- adsorption-measurement methods (MBET/DFT),
- and particle size and packing behavior (apparent density).
Those parameters tend to be interdependent. Moving MBET or DFT usually changes pore distributions and pore volume, which can cascade into other limitations.
What formulation and coating chemistry is protected by US 10,098,997?
Answer: Claims 15–18 protect the polymer coating on the carbon cores, including the polymer families and a weight:weight ratio window.
Coating identity
- Claim 15: hemocompatible polymer-coated carbon cores, where coating includes semipermeable polymer selected from:
- cellulose
- methacrylate polymer
- combinations
- Claim 16: methacrylate options include:
- PMMA
- PEMA
- PHEMA
- combinations
- Claim 17: semipermeable polymer coating is PHEMA
Coating loading window
- Claim 18: carbon:methacrylate weight:weight ratio between 52:1 and 25:1
Coating scope implications
- Literal scope is strongest where the coating is PHEMA or another listed methacrylate, and where loading matches the W/W ratio window.
- A competitor using a different hemocompatible polymer (not cellulose or methacrylate) likely avoids literal infringement, though doctrine-of-equivalents risk remains depending on prosecution history (not provided here).
What cartridge and performance claims add functional drug-specific limitations?
Answer: Claims 9–14 add device form (filter cartridge) and in vitro extraction efficiencies for specific drugs at defined blood flow rates.
Cartridge requirement
- Claim 9: housing is a filter cartridge
Drug-specific extraction efficiencies (dependent)
All of these depend on Claim 9 (filter cartridge), and therefore include the Claim 1 carbon-and-housing limitations plus Claim 9’s cartridge structure.
- Claim 10 (melphalan HCl, 250 mL/min): extraction efficiency > 98%
- Claim 11 (melphalan HCl, 500 mL/min): extraction efficiency 95% to 98%
- Claim 12 (melphalan HCl, unspecified flow in in vitro system): extraction efficiency > 95%
- Claim 13 (doxorubicin, 250 mL/min): extraction efficiency > 95%
- Claim 14 (topotecan, 250 mL/min): extraction efficiency > 89%
Infringement reading for functional limits
Functional parameters are often harder to litigate than structural limitations. However, because the efficiencies are recited as claim limitations, infringement can turn on:
- test method,
- blood source matrix,
- assay endpoints,
- and whether the claimed flow conditions match.
The estate therefore supports both:
- structural infringement theories (carbon properties + coating),
- and performance infringement theories if the accused system is benchmarked at the claimed flow rates.
What is the overall claim matrix (how independent and dependent claims layer protection)?
Below is the layered structure implied by your recited claim set.
| Claim |
Additional limitation beyond Claim 1 |
Key numeric windows |
| 1 |
Filter apparatus; housing inlet/outlet; extraction media = hemocompatible polymer-coated carbon cores; pore volume |
Pore volume: 1.68–2.17 cc/g |
| 2 |
Carbon particle diameter |
0.45–1.15 mm |
| 3 |
Apparent density |
0.19–0.2 cc/g |
| 4 |
Micropore D50 |
9.3–10.5 Å |
| 5 |
Mesopore D50 |
30–156 Å |
| 6 |
% microporous pores |
18–28% (of pore volume) |
| 7 |
MBET surface area |
1825–2058 m²/g |
| 8 |
DFT surface area |
1483–1778 m²/g |
| 9 |
Housing is a filter cartridge |
Cartridge form factor |
| 10 |
Melphalan HCl extraction efficiency |
>98% at 250 mL/min |
| 11 |
Melphalan HCl extraction efficiency |
95–98% at 500 mL/min |
| 12 |
Melphalan HCl extraction efficiency (in vitro system) |
>95% |
| 13 |
Doxorubicin extraction efficiency |
>95% at 250 mL/min |
| 14 |
Topotecan extraction efficiency |
>89% at 250 mL/min |
| 15 |
Semipermeable polymer coating types |
cellulose, methacrylate, combinations |
| 16 |
Methacrylate subtypes |
PMMA, PEMA, PHEMA, combinations |
| 17 |
Specific coating |
PHEMA |
| 18 |
Polymer loading |
carbon:methacrylate = 52:1 to 25:1 |
| 19 |
Re-stated combination (pore volume + MBET + DFT) |
Pore volume 1.68–2.17; MBET 1825–2059; DFT 1483–1778 |
| 20 |
Re-stated DFT surface area range |
1483–1778 m²/g |
Notable observation: Your text shows claims 19–20 as re-statement/recapture around pore volume, MBET, and DFT. That typically functions to reinforce that particular carbon characterization combinations remain covered even if other sub-parameters vary.
How does the claimed pore-volume and surface-area profile constrain competing technologies?
Answer: The numeric windows on pore volume, MBET, and DFT define a specific adsorptive carbon class. Many “activated carbon” products sit outside these combined windows.
Key infringement choke points
- moving pore volume outside 1.68–2.17 cc/g,
- shifting MBET outside 1825–2058 (or 2059 in claim 19),
- shifting DFT outside 1483–1778,
- or changing pore size medians (micro D50 and meso D50) and microporous pore fraction.
What a design-around typically does in practice
- uses a carbon with different pore distribution and functionalization,
- applies a coating polymer outside the specified families,
- or changes packing (particle size/apparent density) and/or device flow regime such that performance does not meet the efficiency thresholds.
Which therapeutic agents are explicitly covered, and are they the only ones?
Answer: The claims explicitly tie performance thresholds to melphalan hydrochloride, doxorubicin, and topotecan. The independent claim language is broader on “small molecule chemotherapy agents,” but drug-specific thresholds are only claimed for those three.
Covered-by-explicit-performance vs covered-by-structural scope
- Structural coverage (Claim 1 + carbon property windows + coating + cartridge) can apply to other small-molecule chemotherapy agents in principle.
- But the evidence burden for other agents would not be supported by claim recitation of their extraction efficiencies.
When does US 10,098,997 expire and how does that affect generic or competing filter timing?
Answer: The expiration date cannot be computed from the provided claim text alone. Expiry depends on the patent’s earliest effective non-provisional filing date and whether it has adjustments or terminal disclaimers. No bibliographic data (filing date, PCT priority, PTA/PTA, continuation links) is provided here.
What does the “Orange Book status” question imply for US 10,098,997?
Answer: The Orange Book lists approved drug products and patents tied to those drugs. A filter apparatus patent like this is typically a medical device or biologics-adjacent process/tool and is not normally Orange Book-listed unless connected to an approved drug product through an applicable patent listing mechanism. No Orange Book listing data for 10,098,997 is provided here.
Is this patent likely to support Paragraph IV-style generic challenges?
Answer: Paragraph IV is relevant to ANDA generic drug approvals of small-molecule drugs. This patent targets a blood filtration apparatus and not an approved drug product dosage form. A Paragraph IV challenge framework does not map cleanly to the mechanism of enforcing this kind of patent against a “generic” filtration product.
What patent litigation risks does the claim structure create for competitors?
Answer: The estate’s risk profile is driven by:
- the tight carbon characterization ranges (structural infringement opportunities and invalidity risk via close prior art carbon adsorbents),
- and the drug-specific performance thresholds (infringement evidence needs benchmarking at claimed flow rates).
Litigation-relevant claim vulnerabilities (based on claim content)
- Measurement method dependence: MBET and DFT surfaces and pore distributions depend on test methods. Competitors can argue different measurement standards yield values outside the range.
- Cartridge/flow conditions: performance limitations are flow-rate-specific, giving accused infringers an evidence path to dispute whether conditions match the claim.
How strong is the patent estate likely to be, given the claim breadth?
Answer: Based strictly on claim language, the estate is stronger on specific carbon-class compositions than on broad “any carbon adsorption detox filter” concepts.
Strength indicators
- numeric ranges define the invention with precision,
- coating chemistry is limited to specific polymer families and loading ranges,
- drug-specific efficiencies provide a performance hook for enforcement.
Weakness indicators
- the tight ranges increase the chance that close prior art exists with overlapping but not identical metrics,
- and they raise design-around options by shifting carbon properties or polymer chemistry outside the claimed windows.
What does this mean for R&D and licensing strategy?
Answer: Commercial and R&D teams should treat the estate as protecting a specific engineered adsorption system, not a general category. A licensing or freedom-to-operate strategy should focus on:
-
Carbon characterization matching
- pore volume,
- MBET/DFT surfaces,
- micro/meso pore distributions,
- microporous pore fraction.
-
Coating identity and loading
- cellulose vs methacrylate vs non-listed polymers,
- PHEMA vs alternatives,
- carbon:methacrylate W/W ratio.
-
Device form factor and throughput
- cartridge configuration,
- and achieved extraction efficiencies at 250 mL/min and 500 mL/min.
Key Takeaways
- U.S. Patent 10,098,997 claims a hemocompatible polymer-coated carbon-core filter cartridge to remove small-molecule chemotherapy agents from blood.
- The independent claim is limited by carbon pore volume (1.68–2.17 cc/g); dependent claims further narrow particle size, density, micropore/mesopore distributions, and MBET/DFT surface areas.
- Coating protection covers cellulose and methacrylate polymers, with PHEMA and a carbon:methacrylate loading ratio of 52:1 to 25:1 as especially targeted dependent territory.
- Drug-specific dependent claims add extraction efficiency thresholds for melphalan HCl, doxorubicin, and topotecan at specified in vitro flow rates.
- The estate’s enforceability and design-around options largely turn on whether an accused product matches the combined quantitative carbon profile plus coating plus cartridge form and, in some cases, performance at claimed throughput.
FAQs
-
Do claims covering melphalan, doxorubicin, and topotecan limit the patent to only those drugs?
No. The independent claim covers small molecule chemotherapy agents generally; the explicit efficiency thresholds are stated only for those drugs.
-
Which claim parameters are most decisive for a carbon adsorbent design-around?
Pore volume plus MBET/DFT surface areas plus micropore/mesopore median diameters and microporous pore fraction.
-
If a competitor uses cellulose instead of PHEMA, do they avoid infringement?
Not if cellulose qualifies under the claim and the rest of the carbon and structural limitations are met; Claim 15 expressly includes cellulose.
-
Can performance-based dependent claims be avoided by changing in vitro flow rate?
The dependent claims are tied to specific flow rates for some drugs (notably 250 mL/min and 500 mL/min). Changing test conditions may reduce the fit to the claim limitation.
-
Does this patent imply an FDA regulatory exclusivity similar to drug Orange Book listings?
The claim is for a filter apparatus; Orange Book regulatory exclusivity frameworks for drug products do not directly apply without an identified listing link (not provided in the input).
References
No external sources were provided in the prompt, and no bibliographic record (e.g., USPTO Patent Center data, claims page for 10,098,997, family information, prosecution history, litigation docket, or Orange Book listing) was included. Without those citations, no compliant reference list can be generated.
